Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,968,128
  • Shares Outstanding, K 1,765,868
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • 60-Month Beta 0.64
  • Price/Sales 5.92
  • Price/Cash Flow 10.95
  • Price/Book 38.00
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 19.72% ( -1.61%)
  • Historical Volatility 22.58%
  • IV Percentile 60%
  • IV Rank 29.90%
  • IV High 29.42% on 04/12/24
  • IV Low 15.58% on 09/01/23
  • Put/Call Vol Ratio 0.62
  • Today's Volume 29,808
  • Volume Avg (30-Day) 16,574
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 324,461
  • Open Int (30-Day) 303,628

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 2.89
  • Number of Estimates 9
  • High Estimate 2.95
  • Low Estimate 2.84
  • Prior Year 2.95
  • Growth Rate Est. (year over year) -2.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
163.52 +13.23%
on 07/03/24
186.85 -0.90%
on 07/26/24
+14.01 (+8.19%)
since 06/26/24
3-Month
153.58 +20.56%
on 05/30/24
186.85 -0.90%
on 07/26/24
+25.54 (+16.00%)
since 04/26/24
52-Week
135.85 +36.30%
on 11/09/23
186.85 -0.90%
on 07/26/24
+43.26 (+30.49%)
since 07/26/23

Most Recent Stories

More News
Why AbbVie Stock Was Cruising Higher on Thursday

The market was impressed with a notable increase in full-year guidance.

ABBV : 185.16 (+1.64%)
AbbVie (ABBV) Q2 2024 Earnings Call Transcript

ABBV earnings call for the period ending June 30, 2024.

ABBV : 185.16 (+1.64%)
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END

TNXP : 0.5500 (-5.09%)
LLY : 804.62 (-2.02%)
PFE : 30.77 (+3.39%)
ABBV : 185.16 (+1.64%)
AXSM : 86.53 (+0.64%)
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

TNXP : 0.5500 (-5.09%)
LLY : 804.62 (-2.02%)
PFE : 30.77 (+3.39%)
ABBV : 185.16 (+1.64%)
AXSM : 86.53 (+0.64%)
Is AbbVie the Best Dividend Stock for You?

The drug company has a famously strong dividend record -- and that looks set to continue.

ABBV : 185.16 (+1.64%)
AbbVie: Q2 Earnings Snapshot

AbbVie: Q2 Earnings Snapshot

ABBV : 185.16 (+1.64%)
Stocks Muted Before the Open as Investors Await Key U.S. GDP Data and Earnings Reports

September S&P 500 E-Mini futures (ESU24) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU24) are down -0.18% this morning as market participants adopted a cautious stance ahead of a fresh...

ESU24 : 5,499.00s (+1.06%)
NQU24 : 19,174.50s (+0.96%)
TSLA : 219.80 (-0.20%)
GOOGL : 167.00 (-0.17%)
LW : 56.71 (+6.98%)
ENPH : 119.34 (+1.55%)
T : 19.01 (-0.94%)
ABBV : 185.16 (+1.64%)
UNP : 240.36 (+2.13%)
NOC : 480.30 (+2.07%)
RTX : 113.95 (+0.42%)
HON : 202.74 (+0.14%)
3 Highest-yielding Dividend Kings That Could Soar

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

FRT : 109.55 (+2.33%)
FRT : 109.55 (+2.33%)
ABBV : 185.16 (+1.64%)
PEP : 172.75 (+1.01%)
AbbVie's EPKINLYâ„¢ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Time-limited reimbursement (TLR) recommendation is a new Canada's Drug Agency (CDA) review process whereby a temporary recommendation is issued based on a...

ABBV : 185.16 (+1.64%)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 61.00 (+4.01%)
UNH : 569.72 (+1.79%)
ABT : 105.24 (-0.68%)
CI : 343.64 (+0.73%)
AZN : 78.13 (-0.50%)
BGNE : 162.54 (-0.45%)
RVNC : 3.92 (+4.26%)
ABBV : 185.16 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 192.04
2nd Resistance Point 189.45
1st Resistance Point 187.30
Last Price 185.16
1st Support Level 182.56
2nd Support Level 179.97
3rd Support Level 177.82

See More

52-Week High 186.85
Last Price 185.16
Fibonacci 61.8% 167.37
Fibonacci 50% 161.35
Fibonacci 38.2% 155.33
52-Week Low 135.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar